Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Alpelisib
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin (PLD)
Drug: Olaparib

First Posted Date: 2021-01-28

Last Posted Date: 2024-11-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 358

Registration Number: NCT04729387

Locations: 🇺🇸
Arizona Oncology Associates, Phoenix, Arizona, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Maryland Oncology Hematology P A, Silver Spring, Maryland, United States

and more 22 locations

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Phase 3

Terminated

Conditions: Platinum-resistant Ovarian Cancer

Interventions: Drug: Batiraxcept
Other: Placebo
Drug: Paclitaxel

First Posted Date: 2021-01-28

Last Posted Date: 2023-10-30

Lead Sponsor: Aravive, Inc.

Target Recruit Count: 366

Registration Number: NCT04729608

Locations: 🇺🇸
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Columbus NCORP, Columbus, Ohio, United States

and more 146 locations

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Phase 1

Recruiting

Conditions: Head Cancer Neck
Head and Neck Squamous Cell Carcinoma
Neck Cancer
HNSCC
Head Cancer
Head and Neck Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Cemiplimab
Drug: Docetaxel
Drug: Cetuximab
Procedure: Surgical Resection of Primary +/- Neck Dissection
Radiation: Post-operative radiation therapy
Drug: Paclitaxel

First Posted Date: 2021-01-25

Last Posted Date: 2024-03-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT04722523

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

Phase 1

Suspended

Conditions: Ovarian Tumors

Interventions: Drug: GRN-300
Drug: Paclitaxel

First Posted Date: 2021-01-15

Last Posted Date: 2024-01-23

Lead Sponsor: Green3Bio, Inc.

Target Recruit Count: 73

Registration Number: NCT04711161

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3

Active, not recruiting

Conditions: Gastroesophageal Junction Adenocarcinoma
Gastric Cancer, Adenocarcinoma

Interventions: Drug: Ramucirumab
Drug: Trastuzumab deruxtecan
Drug: Paclitaxel

First Posted Date: 2021-01-12

Last Posted Date: 2024-10-24

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 490

Registration Number: NCT04704934

Locations: 🇦🇷
Instituto Medico Especializado Alexander Fleming, Colegiales, Caba, Argentina
🇦🇷
IONC Instituto Oncologico de Cordoba - Fundacion Richardet Longo, Nueva Cordoba, Cordoba, Argentina
🇦🇷
Exelsus, San Miguel De Tucumán, Tucumán, Argentina

and more 153 locations

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Phase 2

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Camrelizumab
Drug: S-1
Drug: Oxaliplatin
Drug: Paclitaxel

First Posted Date: 2021-01-05

Last Posted Date: 2024-02-07

Lead Sponsor: Quan Wang

Target Recruit Count: 37

Registration Number: NCT04694183

Locations: 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China

Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

Phase 2

Recruiting

Conditions: Esophageal Adenocarcinoma

Interventions: Drug: Carboplatin
Radiation: 3 Dimensional Conformal Radiation Therapy
Drug: Propranolol
Radiation: Intensity Modulated Radiation Therapy
Drug: Paclitaxel

First Posted Date: 2020-12-23

Last Posted Date: 2024-04-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 106

Registration Number: NCT04682158

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Phase 3

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Pegylated liposomal doxorubicin
Drug: Niraparib
Drug: Paclitaxel
Drug: Dostarlimab
Drug: Gemcitabine
Drug: Topotecan
Drug: Bevacizumab

First Posted Date: 2020-12-22

Last Posted Date: 2021-08-27

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 427

Registration Number: NCT04679064

Locations: 🇮🇹
Istituto Tumori della Romagna IRST IRCCS, Meldola, Italy
🇮🇹
Azienda Ospedaliera Spedali Civili, Brescia, Italy
🇮🇹
IEO-Istituto Europeo di Oncologia, Milan, Italy

and more 5 locations

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Cetuximab
Drug: Paclitaxel

First Posted Date: 2020-12-17

Last Posted Date: 2022-03-23

Lead Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Target Recruit Count: 531

Registration Number: NCT04672772

Locations: 🇪🇸
Hospital Universitario Canarias (TENERIFE), San Cristobal de la Laguna, Tenerife, Spain
🇪🇸
Hospital Universitario Clínico San Carlos, Madrid, Spain
🇪🇸
Hospital Regional Universitario de Málaga, Málaga, Andalucia, Spain

and more 17 locations

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

Phase 1

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: paclitaxel
Drug: IBI318

First Posted Date: 2020-12-17

Last Posted Date: 2023-02-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 20

Registration Number: NCT04672928

Locations: 🇨🇳
Jilin Povince Cancer Hospital, Changchun, Jilin, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy